Valuation: DiaSorin S.p.A.

Capitalization 3.73B 4.34B 3.41B 3.26B 5.97B 416B 6.07B 40.97B 15.85B 198B 16.29B 15.94B 689B P/E ratio 2026 *
21.2x
P/E ratio 2027 * 18.1x
Enterprise value 4.39B 5.11B 4.02B 3.83B 7.03B 490B 7.14B 48.2B 18.65B 233B 19.16B 18.75B 810B EV / Sales 2026 *
3.58x
EV / Sales 2027 * 3.26x
Free-Float
37.17%
Yield 2026 *
1.92%
Yield 2027 * 2.06%
1 day+1.44%
1 week+11.49%
Current month+21.44%
1 month+13.46%
3 months-1.78%
6 months+19.59%
Current year+2.68%
1 week 60.4
Extreme 60.4
71.72
1 month 56.14
Extreme 56.14
71.72
Current year 52.34
Extreme 52.34
77.64
1 year 52.34
Extreme 52.34
95.46
3 years 52.34
Extreme 52.34
112.35
5 years 52.34
Extreme 52.34
208.8
10 years 49.85
Extreme 49.85
211.8
Manager TitleAgeSince
Chief Executive Officer 60 25/03/2007
Director of Finance/CFO - 31/12/2024
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 60 27/04/2016
Director/Board Member 63 25/03/2007
Chairman 57 28/04/2022
Change 5d. change 1-year change 3-years change Capi.($)
+1.44%+11.49%-25.93%-33.24% 4.34B
-3.79%-0.82%+133.39%+248.33% 12.59B
-1.10%+0.77%-40.34%-26.72% 9.82B
-2.86%+0.91%+15.60%-3.61% 6.11B
+5.62%+7.84%-7.35%-9.69% 5.91B
-5.63%-2.30%+87.36%+81.77% 4.57B
-4.59%-9.91% - - 4.11B
-0.89%-1.52%-14.59%-42.78% 2.82B
-1.49%-1.85%+125.77%-59.37% 2.69B
-3.20%-8.69%0.00%+26.69% 1.52B
Average -1.65%-0.79%+30.43%+20.15% 5.45B
Weighted average by Cap. -1.70%+0.18%+38.10%+55.06%

Financials

2026 *2027 *
Net sales 1.23B 1.43B 1.12B 1.07B 1.96B 137B 2B 13.47B 5.21B 64.98B 5.35B 5.24B 226B 1.31B 1.52B 1.2B 1.14B 2.1B 146B 2.13B 14.39B 5.57B 69.45B 5.72B 5.6B 242B
Net income 179M 208M 164M 156M 286M 19.96B 291M 1.96B 760M 9.48B 781M 764M 33.01B 205M 239M 188M 179M 329M 22.91B 334M 2.25B 872M 10.87B 896M 877M 37.88B
Net Debt 660M 766M 603M 575M 1.05B 73.53B 1.07B 7.23B 2.8B 34.91B 2.88B 2.81B 122B 543M 631M 496M 473M 868M 60.51B 882M 5.95B 2.3B 28.73B 2.37B 2.32B 100B
Logo DiaSorin S.p.A.
DiaSorin S.p.A. specializes in the development, manufacturing and marketing of in vitro diagnostic reagents. The products are used in treating infectious and viral diseases, thyroid pathologies, cancer, etc. At the end of 2024, the group had 10 production sites located in Italy, the United States (6), Canada, Germany, and the United Kingdom.
Employees
3,242
Date Price Change Volume
15/05/26 70.46 +1.44% 377,619
14/05/26 69.46 -1.53% 314,519
13/05/26 70.54 +3.31% 470,536
12/05/26 68.28 +2.37% 418,903
11/05/26 66.70 +5.54% 868,262
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
70.46EUR
Average target price
69.86EUR
Spread / Average Target
-0.85%

Quarterly revenue - Rate of surprise